Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants

Finding an effective human immunodeficiency virus type 1 (HIV-1) vaccine remains a major global health priority. In a phase I/II, placebo-controlled trial, healthy, HIV-1-negative adults were randomized to receive one of 5 vaccine regimens: LIPO-5 (combination of 5 lipopeptides) alone (250 μg), ALVA...

詳細記述

保存先:
書誌詳細
出版年:Clin Vaccine Immunol
主要な著者: Frey, Sharon E., Peiperl, Laurence, McElrath, M. Juliana, Kalams, Spyros, Goepfert, Paul A., Keefer, Michael C., Baden, Lindsey R., Lally, Michelle A., Mayer, Kenneth, Blattner, William A., Harro, Clayton D., Hammer, Scott M., Gorse, Geoffrey J., Hural, John, Tomaras, Georgia D., Levy, Yves, Gilbert, Peter, deCamp, Allan, Russell, Nina D., Elizaga, Marnie, Allen, Mary, Corey, Lawrence
フォーマット: Artigo
言語:Inglês
出版事項: American Society for Microbiology 2014
主題:
Vaccines
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4248765/
https://ncbi.nlm.nih.gov/pubmed/25253665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00450-14
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料